Stephanie has an extensive background in commercialising transformative mental health products as well as scaling health technology start-ups across international markets. She has previously held leadership positions within two notable UK based mental health technology companies, supporting both from early-stage start-up to fast growing scale-up.
While at virtual reality technology start-up Oxford VR, Stephanie managed global operational and commercial activity at Director level. Her success includes developing and mobilising a series of large-scale commercial contracts across the UK, US, Asia and Europe.
As one of the founding members of Ieso Digital Health (formerly PsychologyOnline), Stephanie helped the company expand across the NHS, before developing further growth areas outside of the UK which included replicating the business in the US. Stephanie launched the online CBT (cognitive behavioural therapy) service’s first commercial UK contracts with NHS adult and child mental health commissioners and providers. She also managed the clinical operations, including the development and implementation of a highly sophisticated learning and development platform for clinicians that greatly strengthened the company’s value proposition.
Sabine has dedicated more than 25 years to researching the molecular basis of mental illness, co-authoring more than 200 research papers on disorders including bipolar disorder and major depressive disorder. Her research group has contributed to launching the world’s first commercially available diagnostic aid for schizophrenia in collaboration with the NASDAQ-listed diagnostics company Myriad Genetics Inc.
As co-founder of Psyomics Ltd, and head of the Cambridge Centre for Neuropsychiatric Research, Sabine is leading a team of scientists working on developing blood-based tests for bipolar disorder and major depression, as well incorporating evidence-based mental health research into the development of our digital tools. As a practicing psychiatrist at the Cambridge and Peterborough NHS trust, Sabine has direct experience of the clinical need for new digital and biological tools for tackling some of the fundamental challenges in mental health.
David has spent the past 25 years working with more than 50 high growth companies, helping them raise and successfully deploy in excess of £250m from public and private funds, and execute a variety of successful exits including merger, trade sale and IPO. David has also worked closely with financial providers, spending four years as Company Secretary of Prelude Trust plc, a main market listed Investment Trust, and since 2008 he has been CFO of Wyvern Fund, which invests in early stage technology companies. As Chief Financial Officer for Psyomics, David has proven experience in helping businesses build shareholder value, so entrepreneurs and investors alike can achieve their objectives. In addition, much of his previous work has seen him specialise in advising SMEs in the life science and technology arenas.
Kalhari has worked in the UK finance sector for more than 15 years, with five years’ experience as a senior accountant in an audit practice and seven years as a finance manager in the biotechnology sector. She has been an associate member of the Chartered Institute of Management Accountants since 2008. At Psyomics, Kalhari’s experience as a financial controller is invaluable in producing timely, accurate financial information for the board, as well as preparing budgets and business plan forecasts to assist with year-end processes and statutory accounts preparation.
Neil has been a consultant psychiatrist based in Cambridge for more than 20 years, and a member of the Royal College of Psychiatrists since 1987. He has co-authored numerous research papers in leading medical and psychiatric journals including the Lancet, over the past three decades, and is an author of two books including ‘Bipolar Disorder - Your Questions Answered.’ As a member of the Psyomics Advisory Board, Neil’s many years of clinical experience in treating patients with mental illnesses are invaluable in ensuring that our technologies address the needs of clinicians to aid them with early diagnosis, as well as ensuring that they provide patients with appropriate feedback and recommendations for self-help.
Kevin has over 20 years leadership experience running global operations in varied business environments with a focus on the healthcare technology sector. He has an in-depth knowledge and understanding of UK and international healthcare sectors and currently serves as Chairman of Medic Creations Ltd and Jiva.ai Ltd and is the founder and CEO of Datalla Group Ltd.
Kevin is an advisor to several leading companies and is also an accomplished speaker on future trends, growth, scaling, strategy, corporate governance, leadership and organisational development. Previous experiences include Business Director at Capita, Managing Director of EMIS Group Plc’s EMIS Care and EMIS Health Specialist divisions and CEO of Digital Healthcare Ltd.
Kevin’s extensive industry knowledge and direction as Chairman of the board is integral for Psyomics’ commercial growth and ensuring the company achieves its financial, operational and organisational goals.
Anne has 20 years of experience in helping university researchers commercialise their technology, and launch successful independent businesses based on their findings. Anne has been part of the University of Cambridge technology transfer team since 2001, holding a number of roles with Cambridge Enterprise including Head of Technology Transfer, and Head of Seed Funds. During her time with Cambridge Enterprise, Anne has supported numerous early stage companies, serving on the boards of Pneumacare, Cambridge CMOS Sensors, Aqdot, Cambridge Touch Technologies and others. She is also a founding member of Praxis, the UK Technology Transfer Training Programme. As Non-Executive Director on Psyomics’ Board, Anne brings considerable experience in turning research into successful commercial technologies, and delivering value to stakeholders.
Barnaby has been involved in building and growing digital health businesses for the past decade, currently serving as the CEO of Oxford VR, a University of Oxford spinout which uses virtual reality technology to deliver psychological interventions to patients. Barnaby also serves as the director of Tentsmuir Ltd, a company which provides practical support for digital health businesses, raising the funding required to turn innovative ideas into commercial success. As a non-executive director of Psyomics, Barnaby supports the company with its commercial strategy. His experience as founding CEO of Ieso Digital Health is particularly relevant to Psyomics future plans. Over the course of seven years, Barnaby built Ieso to become UK’s leading provider of live online cognitive behavioural therapy, obtaining multiple contracts with the NHS and Medicaid patients in the US, to deliver evidence-based mental health therapy services.
Martin currently serves as an investment director for Parkwalk Advisors, and sits on the board of various portfolio companies, managing investments in UK university spinouts on behalf of EIS clients. Prior to that, he accumulated 25 years experience as a hedge fund manager and equities analyst, focusing on IPOs and follow-on deals. He has also been an Extel-rated analyst and an investment banker at various institutions including Lazard and Jeffries. As a non-executive director, Martin brings extensive experience to the Psyomics Board in terms of commercial and financial strategy.